headlinez.news Live news trend intelligence
▲ Peaking Business 🔮 headlinez.news predicts: fades by tomorrow

Pharma Company And Drug Testing Industry Claim Trump's Rescheduling Move Will 'Increase Marijuana Abuse'

Industry groups and pharmaceutical representatives are challenging President Trump's marijuana rescheduling move as DEA hearings conclude.

5sources
8articles
4velocity
+60%since first seen
1d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

The DEA has officially concluded hearings regarding the federal rescheduling of marijuana. While cannabis industry operators and stakeholders have expressed encouragement following the proceedings, opposition has emerged from within the pharmaceutical and drug testing sectors.

Coverage from Marijuana Moment, MJBizDaily, 9fin, Business of Cannabis, and The Motley Fool emphasizes a divide between industry proponents and those citing concerns over potential increases in marijuana abuse. Reports note that anti-cannabis groups are currently attempting to bar cannabis companies from intervening in legal defense efforts related to the rescheduling.

Future developments hinge on how the legal system addresses requests to exclude marijuana companies from pending litigation. Coverage does not yet specify a timeline for the final regulatory outcome following the close of the hearings.

Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8h ago.

Quick answers

What is the primary concern of the opposition groups?

Pharmaceutical companies and the drug testing industry claim that the rescheduling move will lead to an increase in marijuana abuse.

What happened during the DEA hearings?

The hearings concluded with debate between industry proponents and witnesses; one state witness conceded that regulation reduces crime.

Which companies are being monitored regarding this move?

The Motley Fool identifies Canopy Growth, Green Thumb, and Tilray as companies impacted by the president's policy shift.

Coverage (8)

Topics

DEA Marijuana Donald Trump Cannabis Industry Pharmaceuticals

Related trends